Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Agios Pharmaceuticals Inc (AGIO) USD0.001

Sell:$47.46 Buy:$47.52 Change: $0.23 (0.48%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.23 (0.48%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
Change: $0.23 (0.48%)
Market closed |  Prices as at close on 24 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company's lead product candidate in its genetically defined disease (GDD) portfolio, mitapivat, is an activator for the treatment of hemolytic anemias. The Company’s clinical candidate, mitapivat, is in Phase III studies which is developed for the treatment of pyruvate kinase (PK), deficiency, thalassemia, and sickle cell disease (SCD). The Company is also developing AG-946, a clinical-stage, next-generation oral activator of pyruvate kinase R (PKR) enzymes, which is in Phase I clinical study. The mitapivat is an orally available small molecule and a potent activator of the PKR enzymes.

Contact details

88 Sidney St
United States
+1 (617) 6498600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.76 billion
Shares in issue:
61.57 million
United States
US dollar
NASDAQ Comb. Composite

Key personnel

  • David Schenkein
    Chairman of the Board
  • Jacqualyn Fouse
    Chief Executive Officer, Director
  • Jonathan Biller
    Chief Financial Officer, Head of Legal and Corporate Affairs
  • T. J. Washburn
    Principal Accounting Officer
  • Bruce Car
    Chief Scientific Officer
  • Sarah Gheuens
    Chief Medical Officer
  • Darrin Miles
    Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.